Real biological Azvudin combined with PD-1 monoclonal antibody therapy for advanced solid tumors clinical trial approved by the National Drug Administration.

On February 13th, Henan Zhen Shi Biological Technology Co., Ltd. announced that its self-developed anti-tumor drug GEN-725 in combination with PD-1 monoclonal antibody has been approved for clinical trials in the treatment of advanced solid tumors by the National Medical Products Administration. In the future, Zhen Shi Biological will accelerate the clinical research of Azuvitinib in combination with PD-1 monoclonal antibody in patients with advanced solid tumors.